

Index

- activated platelets 227, 245–48, 323, 342, 398
- activation, excessive 365
- activation state 244–45, 247, 255–56
- acute coronary syndromes 169, 236, 318, 350, 392, 400, 403
- acute myocardial infarction (AMI) 174
- AFM, *see* Atomic force microscopy
- Alzheimer disease 14, 18
- AMI, *see* acute myocardial infarction
- angiogenesis 12–13, 19, 90, 93, 95, 140, 236, 303, 317, 323, 326, 372, 399, 402
- anticoagulants 16, 142–44, 149, 186, 230, 344
- antigen-presenting capacity 431, 439
- antigen-presenting cells (APCs) 48–51, 89, 398, 402, 423, 426–27, 430–31, 442
- antigens 10, 20, 49, 84, 89, 202, 211–12, 214–15, 224, 344–45, 359, 367, 377, 438–40, 442
- antithrombotic therapies 189, 193
- APCs, *see*
 - antigen-presenting cells
 - interacting 426–27
- apoptosis induction 309, 424, 426, 428, 446
- apoptotic bodies 3, 6, 140, 285–86, 318, 338, 370, 373–74
- apoptotic cells 19, 437
 - clearance of 19, 437
- arachidonic acid 11, 253–54, 398
- arthritis, collagen-induced 437–38
- assays
 - functional 112, 163, 165, 170, 351, 423
 - procoagulant phospholipid 168–69, 174
- atherosclerotic plaques 2, 5, 350, 398–400, 429
- atomic force microscopy (AFM) 123, 131, 161, 223–32, 279, 324, 344, 421
- autologous exosome immunotherapy 17
- autophagy 52, 58, 68
- B-cells 401, 423, 431, 434, 438, 442
 - activated 49, 51, 84
 - exosome-producing 58
- biological fluids 3, 5, 14, 86, 97, 170, 262, 268, 276, 278, 286, 373
- biomarkers 19–20, 150, 286, 297, 318, 324, 346–47, 349, 351, 369, 378, 404
- blood
 - circulating 164, 235
 - citrated 144, 147
 - healthy 290–91, 293
 - venous 161
- blood activation 149, 182, 184, 189, 191
- blood cells 139, 181–82, 184, 190, 239, 244, 285, 288, 305
 - intact 237

- blood circulation 182, 403
- blood coagulation 201, 226, 322, 340, 400
- blood collection 141–42, 144, 149–50, 167, 186, 230
- blood plasma 86, 295
 - human 274
- blood plasma microvesicles 271
- blood sampling 145, 186
 - logistics of 147, 149
- blood storage 400
- blood vessels 164, 338
- blood–brain barrier 18
- body fluids 1, 66, 86, 107–8, 111, 159, 343, 420
- bone marrow cells 95
- Brownian motion 110, 114, 118, 122, 262–64, 266, 422
- bystander cells 94, 427
 - immune-activating 440
 - immune-suppressive 440
- C-reactive protein (CRP) 394, 396
- calcium 142, 182, 185, 188, 213, 320, 393
- calcium ionophore 228, 248, 252
- calibrated automated thrombogram (CAT) 168
- calibrated polystyrene beads 206
- cancer 12–13, 88–89, 94, 140, 169, 173, 175, 184, 201–2, 317–20, 322–24, 326, 328–29, 346–48, 350
- cancer cells 13, 87, 92–93, 160, 164, 319
 - breast 128, 322
 - malignant 318
 - renal 94
- cancer microvesicles 317
- cancer stem cells 94
- capture-Based Assays 182–84, 192
- CAT, *see* calibrated automated thrombogram
- cell culture supernatants 173, 268, 423, 425–27
- cell cultures 3, 20, 287, 300, 309
- cell debris 211, 213, 310
- cell-derived vesicles 2–3, 5–7, 9, 11, 13, 15, 19–20, 419–20
 - functions of 6–7, 9, 11, 13, 15
- cell lines, breast cancer 13, 256–57
- cell surface proteins 182, 301
- cell-to-cell communication 83, 85, 317, 325–26
- cell-derived exosomes
 - dendritic 399
 - endothelial 84, 88
 - immune 48
 - tumor 84
- cells
 - cancerous prostate 86
 - eukaryotic 20, 52
 - glial 80
 - immune system 89
 - infected 86, 424
 - injured 95–96
 - intact 211, 238, 247
 - lymphocytic 289–90
 - mammalian 48, 53–55, 61, 67
 - metazoan 53, 55
 - myeloid 8, 341
 - nonimmune 424
 - parental 118, 139, 338, 420, 427, 432, 438
 - tubular 96
 - vascular 140, 201, 395
 - virus-infected 9, 15
- ceramide 4, 57, 61–62, 81, 87
- cholesterol 60–61, 64, 160, 320, 350, 429, 444
- coagulation 8–9, 16–17, 140, 161, 163, 166, 174, 186, 296, 299, 310, 323, 337, 341–42, 346

- coagulation activation 19, 161, 174, 342, 346
 coagulation cascade 163, 337, 339–40, 365
 CRP, *see* C-reactive protein
 culture supernatants 362–64, 425
 cytokines 79–80, 160, 326, 365, 393–94, 426, 429
 cytometry 130, 290, 347–49
 cytoplasm 21, 53–54, 65, 83–84, 86, 303
 cytotoxic T-cells 10, 17, 50, 423
- DCs, *see* dendritic cells
 deep venous thrombosis (DVT) 292, 299
 dendritic cell-derived vesicles 431, 433, 435, 437
 dendritic cells (DCs) 2, 240, 420, 430–32, 434–35, 437, 440
 dexosomes 2
 diabetes 173, 348, 392, 403, 424
 DIC, *see* disseminated intravascular coagulation
 disseminated intravascular coagulation (DIC) 16, 205, 236
 DLS, *see* dynamic light scattering
 DNA 6, 14, 21, 86, 111, 140, 319, 338, 369–71
 placental vesicle 369
 double centrifugation procedure 167
 DVT, *see* deep venous thrombosis
 dynamic light scattering (DLS) 114, 118, 123, 126, 129–31, 161, 237, 279, 324, 344
- ectosomes 3, 80, 318–19, 321, 401, 420–21
 EGFR, *see* epidermal growth factor receptor
 electrokinetic fingerprint 244–45, 247–48
- electron microscopy 47, 58, 123, 162, 202, 236, 275, 278, 343, 373, 421, 424, 441–47
 electrophoretic mobility 238–40, 242, 244–46, 248
 embryonic stem 67, 85
 endocytic pathways 48, 52, 58
 endoplasmic reticulum 47
 endosomal membranes 52, 54, 433
 endosomal proteins 420
 endosomes 56, 58–60, 63–64, 83, 235, 343
 endothelial cells 6–7, 11–13, 17, 19, 86, 93, 160–62, 214–15, 325–27, 340–42, 364–66, 377, 393–96, 398–99, 401–2
 activated 215, 342, 398
 human brain 325
 human brain microvascular 326
 proliferation of 13, 93
 quiescent 85, 402
 transfected 325
 tumor 91
 endothelial cells function 302, 364
 endothelial dysfunction 303, 364, 366–67, 375–76, 392
 acute 392, 400
 endothelial progenitor cells (EPCs) 85, 95, 97, 289, 304
 endothelial vesicle formation 394
 endothelial vesicle release 394, 403
 endothelium-derived microvesicles 303
 enzyme-linked immunosorbent assay 185, 324, 345, 359
 EPCs, *see* endothelial progenitor cells
 epidermal growth factor receptor (EGFR) 9, 12, 80, 93, 214, 320, 325

- epithelial cells 15, 21, 91, 160
 human airway 12
 intestinal 10
- epitopes, extracytoplasmic 187
- erythrocytes 2, 139, 160–62, 181, 183, 214, 236, 290, 304–7, 320, 345, 395
- erythroleukemic cells 63, 326
- eukaryotic vesicles 3, 21
- exosomal markers 66, 140
- exosomal sorting 55–56
- exosome biogenesis 4, 15, 47–48, 50–52, 54–58, 60, 62–64, 66–68, 80, 89, 306, 321, 322, 420
- exosome characterization 278
- exosome-like vesicles 3
- exosome physiology 54–55
- exosome proteome 287, 306
- exosome proteomics 294
- exosome release 81
- exosome secretion 11, 13, 15, 48–50, 52, 59–60, 62–67, 81, 305, 310
- exosomes 2–20, 47–60, 62–68, 80–83, 85–93, 159–61, 278–80, 285–87, 297–98, 304–10, 320–22, 343, 372–75, 399–403, 420–21
- B-cell-derived 308–9
- cancer-derived 328
- cancerous 325
- macrophage-derived 308
- markers of 343
- mixture of 373–74
- placenta-derived 369
- plasma-derived 298
- platelet-derived 401
- T-cell-derived exosomes 420, 425
- urinary 295
- extravillous cytotrophoblast 359, 361, 367, 369
- FEM, *see* fracture electron microscopy
- fetal DNA 370
- fetal growth restriction (FGR) 360–61
- FFFF, *see* flow-field flow fractionation
- FGR, *see* fetal growth restriction
- fibrinogen 126, 299, 368
- fibrinolysis 364, 367
- flow cytometers 113, 119–20, 202, 236, 278, 422
- flow cytometry 119, 121, 161–63, 201–2, 204, 206, 208, 210, 236, 255, 274–75, 278–79, 310, 344, 370
- flow-field flow fractionation (FFFF) 109–11, 126, 129, 131
- fluid cells 124–25, 127
- fluid tapping mode 223, 227, 230, 232
- fluorescence 112, 117–19, 122, 129–30, 202–4, 274, 442
- fracture electron microscopy (FEM) 124, 131
- GFP, *see* green fluorescent protein
- giant unilamellar vesicles (GUVs) 57
- Glanzmann thrombasthenia platelets 161
- glioblastoma cells 13, 87, 214
 human 343
- glioma cells 13, 91, 325–26
 human 325–26
- green fluorescent protein (GFP) 85, 325
- GUVs, *see* giant unilamellar vesicles
- HDL, *see* high-density lipoprotein
- hemoglobin concentration 238
- hemolysis 141, 167–69, 288
- hemostasis 205

- heparin 142–44
 heterogeneous vesicle populations 422
 high-density lipoprotein (HDL) 81, 87, 350, 372, 396, 429
 HIV, *see* human immunodeficiency virus
 human atherosclerotic plaques 12, 16, 306, 350
 human blood 13, 191, 300
 human immunodeficiency virus (HIV) 5, 9, 14–15, 85, 317–18
 human monocytes 8, 400, 428
 human plasma 4–5, 7, 187, 201, 205, 214, 243, 280, 345
 human platelets 245, 248, 254
 human umbilical vein endothelial cells (HUVECs) 280, 303–4, 364, 377, 400
 HUVECs, *see* human umbilical vein endothelial cells
 hypoxia 88, 343, 371–72

 IDL, *see* intermediate-density lipoprotein
 immune activation 430, 437
 immune cells 10, 48, 51, 65–66, 89–90, 97, 364, 427, 429, 437, 440
 immune surveillance 90, 327
 immunoglobulins 274, 295, 298, 378, 399
 immunosuppressive exosomes 88
 intermediate-density lipoprotein (IDL) 297

 Jurkat T-cells 443–45

 kidney 337

 late endosomes 52, 59–60, 64, 321
 LDL, *see* low-density lipoprotein
 leukemia 328

 leukocytes 12, 142, 160–62, 181, 183, 214–15, 307, 361, 377, 392, 398, 401
 light scattering
 electrophoretic 242
 multiangle 129
 lipoprotein particles 231
 low-density lipoprotein (LDL) 81, 231, 297, 392
 lymphocyte-derived microvesicles 308

 major histocompatibility complexes (MHC) 8–10, 48, 89, 308, 359, 420, 424–25, 440–41, 443, 446
 malignant cells 184, 214, 325
 MAPK, *see* mitogen-activated protein kinase
 mass spectrometry 286, 295, 300, 305, 309, 366
 maternal blood 357–61, 369–70, 373
 maternal circulation 358–60, 363, 365, 370, 375–78
 maternal plasma 359, 361, 367, 370, 377
 maternal syndrome 360–61, 364, 375
 matrix metalloproteinases 91, 327, 400
 MDMs, *see* monocyte-derived macrophages
 membrane proteins 304, 308–9
 vesicle-associated 432
 mesenchymal stem cells (MSCs) 86, 96, 280, 402
 metabolic syndrome 183, 392, 400
 metalloproteinases, matrix 9, 12–13, 372
 metastasis 12, 14, 91–92, 94, 169, 317, 322, 326–27

- MHC, *see* major histocompatibility complexes
- micro-RNAs 13, 81, 132, 140, 321, 369, 402–3, 405, 426
- lysophosphatidic acid-containing 11
 - macrophage-derived 307
 - phagocytose 20
 - placental 370
 - platelet 392
 - reticulocyte-derived 304
- mitogen-activated protein kinase (MAPK) 91, 95, 325
- monoclonal antibodies 182, 184, 223, 345, 359
- monocyte-derived macrophages (MDMs) 308
- monocytes 11–12, 83, 85, 91, 93, 164, 181, 307, 341, 377, 395–96, 398, 400–2, 429–30, 444–45
- monocytic cells 291
- MSCs, *see* mesenchymal stem cells
- multivesicular bodies 2, 140, 235, 321, 374, 420
- myeloid-derived suppressor cells 8
- naive T-cells, activation of 433
- nanoparticle tracking analysis (NTA) 122, 126, 130, 161, 261–70, 272–76, 278–80, 344, 373–74, 422, 432
- natural killer (NK) 7, 215, 327–28, 363, 432
- neutrophils 160, 164, 323, 341, 364–65, 401
- NK, *see* natural killer
- NK cell activation 435–36
- NK cells 8, 92, 435–37
- normal plasmas 160, 162, 172, 188, 190
- normal pregnancy 7, 11, 174, 357–58, 360–62, 364–66, 368, 370, 372, 374–78
- NTA, *see* nanoparticle tracking analysis
- nucleic acids 67, 81, 85, 97, 214, 226, 369
- OMVs, *see* outer-membrane vesicles
- optical detection methods 112–13, 115, 117, 119, 121, 126–27
- outer-membrane vesicles (OMVs) 21, 57
- ovarian cancer 20, 327–28
- oxidative stress 88, 360, 370–71, 393, 395–96
- P-glycoprotein 13
- pancreatic cancer 173, 324, 350
- pancreatic cancer cells 214
- PBMCs, *see* peripheral blood mononuclear cells
- PBS, *see* phosphate buffered saline
- PDGF, *see* platelet-derived growth factor
- PDI, *see* protein disulphide isomerase
- pericardial blood 161
- peripheral blood 20, 350, 359
- peripheral blood mononuclear cells (PBMCs) 8, 15, 340, 365, 368
- peripheral circulation 359
- PFV, *see* platelet-free plasma
- phorbol myristate acetate (PMA) 423, 444–45
- phosphate buffered saline (PBS) 125, 127, 264, 272, 275, 277–79, 294
- phospholipids 21, 82, 162, 165–66, 168, 191, 213, 401, 403

- photodiode 208, 224–25
 physiology 52, 66, 163
 placenta 202, 337, 357–59,
 362–63, 367–69, 371, 373,
 375–76
 normal 174, 365, 367
 placental insufficiency 369
 placental vesicle mRNA integrity
 371
 placental vesicle protein
 expression 366
 placental vesicles 358–71, 373,
 375–76, 378
 circulating 360–61, 368,
 370–71
 immunosuppressive effects of
 363, 367
 perfused 368, 374
 plaque-derived microvesicles 306
 plasma
 pathological 188, 190–92
 platelet-free 146, 186, 345
 plasma exosomes 297–98
 plasma membrane 2, 4–6, 50–55,
 59–60, 62–67, 81, 83–84,
 89, 112, 318–21, 374, 420,
 427, 433, 438
 plasma microvesicles 272, 278,
 295, 298
 plasma proteins 286, 294, 297,
 310
 plasminogen activator inhibitors
 367, 396, 398
 platelet activation 84, 141, 147,
 160, 245, 248, 253, 288,
 301–2, 320, 377, 394
 platelet-derived growth factor
 (PDGF) 326, 396
 platelet-derived microparticle
 enumeration 226
 platelet-derived microvesicles
 226, 296, 300
 platelet dust 2, 162, 164, 318
 platelet-free plasma (PFP) 143,
 146–49, 151, 186, 294,
 300, 345
 platelet function 144, 243, 301
 platelet microparticles 248
 platelet-poor plasma (PPP) 143,
 146, 151, 168, 171, 227,
 288, 294, 297–99, 345–46
 platelet-rich plasma (PRP) 165,
 168, 248, 253–54, 288, 345
 platelet surface 245–46, 338
 platelet thrombotic action 299
 platelets, thrombin-activated 227
 PMA, *see* phorbol myristate acetate
 polydispersity 244, 268–69
 PPP, *see* platelet-poor plasma
 pre-eclampsia 357–58, 360–62,
 364, 366, 368, 370, 372,
 374, 376, 378
 pre-eclampsia placentas 174,
 364–65, 368, 372, 375
 preanalytical parameters 141,
 143, 145, 148, 150, 287,
 310
 preanalytical variables 108,
 139–40, 142, 144, 146,
 148–50, 166, 172, 183,
 186, 224, 250
 pregnancy 174, 357–61, 363–64,
 367, 372–73, 375–78
 pregnancy loss, late 174
 pregnancy plasma 360
 premetastatic niche 91–92, 94
 procoagulant 144, 163, 170,
 181–82, 184, 192–93, 307,
 340, 366, 375
 procoagulant activity 142,
 144–46, 148, 162–65, 168,
 170, 183, 187, 286, 303,
 338–40, 342, 345, 366, 375
 procoagulant phospholipid activity
 164, 167, 169
 procoagulant phospholipids
 164–65, 169
 progenitor cells 402
 human endothelial 85

- prognostic significance 174
- prostate cancer 328
- prostate cancer cells 93
- prostate cancer patients 20
- protective immunity 10
- protein cargo, complex 368–69
- protein content 62, 307–8
- protein delivery 67, 91
- protein disulphide isomerase (PDI) 170, 303, 368
- protein sorting 2, 4, 55, 57, 60, 67, 298, 420
- proteins
 - activated 184, 396, 398, 402
 - clotting 338
 - exosome 295
 - galectin-3-binding 299
 - high-molecular-weight 108, 126
 - platelet 304
 - prothrombotic 300
 - transmembrane 4, 419
- proteome, plasma-membranous vesicle 295
- proteomic analysis 55, 89, 286–87, 303, 306, 310–11, 368–69
- proteomic analysis of placental vesicles 368
- proteomic approach 304, 307–9
- prothrombin 165, 168, 182, 185, 320, 338
- PRP, *see* platelet-rich plasma
- QELS, *see* quasi elastic light scattering
- quasi elastic light scattering (QELS) 114, 237–40, 242
- recipient cells 14, 21, 48, 59, 67, 81, 83–87, 91, 93, 96–97
- red blood cells (RBCs) 47, 145, 167, 300, 305, 375–77
- resistive pulse sensing (RPS) 124–27, 131
- responder T-cells 442
- ribonucleoproteins 87
- RPS, *see* resistive pulse sensing
- scanning electron microscopy (SEM) 6–7, 124, 131, 252, 398
- SCD, *see* sickle cell disease
- Scott syndrome 183, 320–21
- scramblase 80, 82, 236, 320, 393
- secretory lysosomes (SLs) 50, 54, 59, 62, 64–65, 424
- self-diffusion coefficients 237–39
- SEM, *see* scanning electron microscopy
- shedding microvesicles 3
- sickle cell disease (SCD) 169, 174, 341, 346
- SLs, *see* secretory lysosomes
- smooth muscle cells 164, 307, 337, 392, 398
- statins 403–4
- stem cell biology 88, 94–95, 98
- stem cell plasticity 95, 98
- stem cells
 - human neural 111
 - mesenchymal 280, 402
 - renal cancer 94
- stromal cells 362
- supernatants 114, 228, 303–5, 398
- suppression, immune 7–9, 430, 437
- syncytiotrophoblast 11, 357–59, 362–63, 375
- syncytiotrophoblast vesicles 273, 275, 358–61, 367
- T-cell activation 399, 433–34, 441–47
- T-cell apoptosis 8, 327
- T-cell clones 423, 433–34, 442
- T-cell-derived vesicle-associated miRNAs 426

- T-cell-derived vesicles 423–31, 439–41, 443, 445, 447
 - activated 429
 - isolated 424
 - pleiotropic effects of 430–31
- T-cell-mediated killing of
 - pancreatic beta cells 426
- T-cell plasma membrane proteins 432
- T-cell proliferation 425, 433, 435–36, 441
- T-cell receptor (TCR) 420, 424, 428, 431, 440–43, 446
- T-cell vesicles 428
 - activated 429
- T-cells
 - activated 7, 84, 429, 439
 - anergic 427, 442
 - anti-CD28-activated 429
 - bystander 440
 - effector 431
 - maternal 367
 - naive 49, 433
 - nonactivated 429
 - nonanergic 427
 - primary 423
 - regulatory 423, 427, 431
 - splenic 436
- T-lymphocytes 377, 399, 441, 444–45
- TCR, *see* T-cell receptor
- TEM, *see* transmission electron microscopy
- TFPI, *see* tissue factor pathway inhibitor
- TGA, *see* thrombin generation assay
- TGT, *see* thrombin generation test
- thrombin generation 148, 163, 171, 174, 182, 185, 192, 322, 337, 346
- thrombin generation assay (TGA) 168, 171
- thrombin generation test (TGT) 168, 172–73
- thrombin receptor agonist peptide (TRAP) 253
- thrombocytopenia 169
- thrombocytopenia 326
 - heparin-induced 183
- thromboembolic events 191
 - venous 324, 350
- thrombogenesis 298
- thrombolysis 348
- thromboprophylaxis, primary 324
- thrombosis 119, 166, 183, 205, 226, 310, 317, 322–24, 340, 350–51, 392, 398
- thrombotic diseases 189
- thrombus 15–16, 173, 299, 323, 325, 338
- tissue factor 8–9, 19, 161, 163–64, 170, 172–74, 182, 186–87, 190–91, 224, 228, 253, 322–23, 337–51, 392
- tissue factor expression 366
- tissue factor pathway inhibitor (TFPI) 173, 340–42
- TNF, *see* tumor necrosis factor
- tourniquet 141–42, 186
- transmission electron microscopy (TEM) 3–5, 7, 114–15, 123–24, 131, 278–79
- TRAP, *see* thrombin receptor agonist peptide
- trojan exosome hypothesis 15, 85
- tumor cells 8–9, 13–14, 67, 83–85, 88, 91–92, 94, 160, 236, 318, 325–26, 328, 424
 - green fluorescent protein-labeled 325
 - heat-stressed 88
- tumor microenvironment 90–91, 97
- tumor necrosis factor (TNF) 81, 88, 327, 394, 399, 430
- tumors 13–14, 17, 19, 48, 84, 89–91, 94, 202, 323, 325, 328, 350, 435
- type II diabetes 348

- ultracentrifugation 3, 114–15, 160, 164, 173, 271, 274, 287, 289–93, 301, 303, 306, 308–9, 362, 370
 - analytical 126
- vascular endothelial growth factor (VEGF) 9, 12–13, 80, 91, 94, 323, 325–26, 360, 372
- vascular injury 15–16, 325
- VEGF, *see* vascular endothelial growth factor
- venepuncture 141–42, 224, 232
- venous thromboembolism 173, 323, 349
- venous thrombosis 298–99
 - experimental 298
- very low-density lipoprotein (VLDL) 231, 297
- vesicle detection 112, 118–21
- vesicle isolation 108–9, 122, 441–47
- vesicle labeling 209, 276
- vesicle secretion 8–9, 11
- VLDL, *see* very low-density lipoprotein
- von Willebrand factor (VWF) 126, 246–47, 300, 398
- VWF, *see* von Willebrand factor